Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.49 |
| ▸ | MTTP | P55157 | 6/20 | 0.48 |
| ▸ | APOB | P04114 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | METAP2 | P50579 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | SMO | Q99835 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7041114 | 0.93 | HTT (0.47) | KMT2AHTTMTTPAPOBMAPT | |
| SCHEMBL7041096 | 0.91 | MTTP (0.51) | SORT1MTTPAPOBSMO | |
| SCHEMBL7043296 | 0.90 | MTTP (0.57) | MTTPAPOB | |
| SCHEMBL7041370 | 0.90 | MTTP (0.49) | MTTPAPOBSMO | |
| SCHEMBL7039772 | 0.89 | MTTP (0.53) | MTTPAPOB | |
| SCHEMBL7035895 | 0.86 | MTTP (0.51) | MTTPAPOB | |
| SCHEMBL7035884 | 0.86 | MTTP (0.51) | MTTPAPOB | |
| SCHEMBL7040053 | 0.86 | TRPV1 (0.50) | MTTPAPOBSMO | |
| SCHEMBL7039276 | 0.85 | MTTP (0.44) | MTTPAPOBSMO | |
| SCHEMBL7043268 | 0.85 | MTTP (0.50) | MTTPAPOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-08-28 | — | — | US | disclosed |
| US-20030073836-A1 | Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | APOB, LIPC, MTPN | KMT2A 4321/4885HTT 1297/4885SORT1 519/4885 |
| US-20030073836-A1 | Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | MTTP, CETP, CES1 | KMT2A 2209/4885HTT 1259/4885SORT1 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.